Who Is Sigyn Therapeutics?
We are a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (“The Cytokine Storm” or CSS) and not addressed with an approved therapy. Our mission is to save lives.
About Cytokine Storm Syndrome
Cytokine Storm Syndrome is a life-threatening immune response that can be initiated by a wide-range of infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of inflammatory particles that can trigger multiple organ failure.
A Broad-Specturm Strategy to Deplete Life-Threatening Inflammatory Targets from the Bloodstream
To overcome the limitations of previous drugs and devices, we designed Sigyn Therapy to deplete the presence of a broad-spectrum of inflammatory targets from the bloodstream.
An Expansive Pipeline of Therapeutic Opportunities
Our therapeutic opportunities include, but are not limited to sepsis, virus induced Cytokine Storm (VICS), which is a leading cause of COVID-19 deaths, bacteria induced Cytokine Storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. Cytokine Storm Syndrome may also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.
50+ Years of Relevant Industry Experience
Our co-founders Jim Joyce and Craig Roberts have 50+ years of combined experience in the medical technology field. Additionally, Mr. Joyce has two decades of public company CEO and Corporate Board leadership experience.